Arena’s APD418 Receives FDA’s Fast Track Designation to Treat Patients with Decompensated Heart Failure

 Arena’s APD418 Receives FDA’s Fast Track Designation to Treat Patients with Decompensated Heart Failure

Arena’s APD418 Receives FDA’s Fast Track Designation to Treat Patients with Decompensated Heart Failure

Shots:

  • The US FDA has granted FT designation to APD418, currently in development for the treatment of DHF
  •  The FDA’s Fast Track designation facilitate the development and expedite the review of therapy to treat serious conditions and fill an unmet medical need
  • APD418 is a first-in-class β3-adrenergic receptor (AdrR) antagonist and cardiac myotrope, designed to improve cardiac contractility with minimal effect on HR, BP & myocardial oxygen consumption

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: PRNewswire

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post